Six individuals serve as Senior Leaders of the Memorial Sloan Kettering Cancer Center (MSK). Craig Thompson, MD, MSK?s President and Chief Executive Officer, is the Director of this NCI-supported Comprehensive Cancer Center. Dr. Thompson sets the strategic vision for the Cancer Center and works with MSK?s Board of Overseers and Managers to provide stable governance and financial support of MSK. He ensures that the cancer-focused mission of the Center is relevant to the Center?s catchment area and fosters outreach to its diverse population. Jos Baselga, MD, PhD, Physician-in-Chief, Memorial Hospital (MH), serves as the Deputy Director, MH. He oversees and guides the clinical and population-based research programs to excel in their disciplinary areas, and he sets standards for the infrastructure to support the clinical research review and monitoring, and data management. Dr. Baselga also ensures that training for clinicians and biomedical professionals is conducted with the highest standards. Joan Massagu, PhD is the Director of the Sloan Kettering Institute (SKI) and serves as Deputy Director, SKI. In this role he oversees the laboratory research programs and establishes standards for recruitment and retention of outstanding scientists. Dr. Massagu oversees the core facilities of the Center and manages the research budget in order to provide cutting-edge scientific support for the Center members. Dr. Massagu oversees the training programs for pre- and postgraduate laboratory researchers. Colin Begg, PhD is the Associate Director for Population Science, Larry Norton, MD is the Associate Director for Clinical and Translational Science, and Kathryn Anderson, PhD is the Associate Director for Basic Science. The Associate Directors facilitate transdisciplinary research among the basic, bridge, clinical and population science programs and provide a conduit for bottom-up communication from the Program Leaders/Members to the Senior Leadership team. In overseeing the Cancer Center activities, the Senior Leadership relies on the counsel of outside advisors, represented by its Board of Scientific Consultants (BSC), the guidance of its Board of Overseers and Managers, as well as many internal planning processes to support the planning and evaluation of the research programs and core facilities at the Center. MSK has used the guidance it has received to develop and execute its initiatives for research and clinical expansion. During the past five years, the BSC has reviewed the research in the programs as well as MSK?s Community Outreach and Engagement efforts. BSC members review with Senior Leadership evolving technologies that support cancer research and advise on core service offerings. The BSC has also reviewed newly recruited junior investigators and the training programs that bring outstanding students to MSK?s laboratories. The recommendations made by the BSC and other planning groups have led to program reorganizations, new faculty recruitments, shared resource development, and facility expansions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084838
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Attiyeh, Marc A; Chakraborty, Jayasree; Gazit, Lior et al. (2018) Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. HPB (Oxford) :
Liu, Dazhi; Offin, Michael; Harnicar, Stephen et al. (2018) Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag 14:1247-1252
Corso, Giovanni; Veronesi, Paolo; Sacchini, Virgilio et al. (2018) Prognosis and outcome in CDH1-mutant lobular breast cancer. Eur J Cancer Prev 27:237-238
Choueiri, Toni K; Hessel, Colin; Halabi, Susan et al. (2018) Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eu Eur J Cancer 103:287
Sanabria, Alvaro; Kowalski, Luiz P; Shah, Jatin P et al. (2018) Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis. Head Neck 40:855-866
Zheng, Jian; Sadot, Eran; Vigidal, Joana A et al. (2018) Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS One 13:e0200776
Yaeger, Rona; Chatila, Walid K; Lipsyc, Marla D et al. (2018) Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell 33:125-136.e3
Ghebrehiwet, Berhane; Kandov, Evelyn; Kishore, Uday et al. (2018) Is the A-Chain the Engine That Drives the Diversity of C1q Functions? Revisiting Its Unique Structure. Front Immunol 9:162
Jonsson, Philip; Taylor, Barry S (2018) Transforming Biomarker Development with Exceptional Responders. Trends Cancer 4:3-6
Finley, Lydia W S; Vardhana, Santosha A; Carey, Bryce W et al. (2018) Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity. Nat Cell Biol 20:565-574

Showing the most recent 10 out of 8799 publications